Drugs in Development for Tuberculosis

摘要: Tuberculosis (TB) drug research and development efforts have resurged in the past 10 years to meet urgent medical needs, but enormous challenges remain. These needs are largely driven by current long arduous multidrug regimens, which significant safety, tolerability compliance issues; rising disturbing rates of multidrug- extensively drug-resistant TB; existence approximately 2 billion individuals already latently infected with Mycobacterium tuberculosis, causative pathogen a global TB-HIV co-epidemic. Stakeholders TB moving enable streamline registration novel, treatment comprised multiple new chemical entities novel mechanisms action that do not demonstrate cross-resistance first- second-line drugs. Ideally, these regimens will ultimately provide short, simple suitable for essentially all patients, whether sensitive or resistant anti-TB agents, HIV-positive -negative, irrespective patient age.